Amgen's experimental weight loss injection, MariTide, showed up to 20% weight loss in patients without diabetes and 17% in ...

Pfizer Inc. (NYSE: PFE), and AstraZeneca plc (NASDAQ: AZN) may have faded from the spotlight since the peak of the COVID-19 ...

Eli Lilly’s strong position in GLP-1 drugs is overlooked by the market. Find out why LLY stock is a buy even as others pull ...

The Biden administration is proposing Medicare and Medicaid coverage for glucagon-like peptide 1 receptor agonist (GLP-1 RA) ...

Eli Lilly and Company (NYSE:LLY – Get Free Report) saw some unusual options trading on Tuesday. Investors bought 66,549 call options on the company. This represents an increase of approximately 37% ...

It’s unclear what impact a change in presidential administration will have on the proposal to widen access for those with obesity.

A new Biden administration proposal could allow millions of Americans with obesity to access weight-loss drugs like Wegovy ...

Eli Lilly topped the list of the 20 biggest pharmas by market cap with a more than 39% improvement year-to-date in its share ...

Eli Lilly & Co (LLY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Mohit ...

Pharmaceutical stocks make great additions to any portfolio in any market environment. A good one promises steady revenue ...

Amgen didn't clarify whether the average weight reduction of up to about 20% was a placebo-adjusted figure. It most likely referred to total weight loss, which means the candidate probably isn't any ...

More than seven million additional Americans could get coverage for popular drugs such as Zepbound and Wegovy under the ...